Fluidigm’s products typically consist of single-use biochips, instrumentation for handling biochips and software for instrument operation and data collection and analysis. No Fluidigm products had been approved for clinical use in the United States as of 2009. The company completed a successful initial public offering in February 2011, raising about $75 million. As of the 2011 IPO, Fluidigm had not yet become profitable, but had accumulated nearly $200 million in debt. Following a $250 million investment from Casdin Capital and Viking Global Investors in April 2022, Fluidigm changed its name to Standard BioTools. Going into 2015, the company is making an effort to infuse industrial design, aesthetic and customer centricity principles to help distinguish their products from those of competitors and generate a distinctive brand experience for users.
- Broker recommendations are issued over a particular period of time.
- A former bank regulator is blowing the whistle on Biden’s frightening plan to take over your money.
- EPS is the net income, or profit, a company generates during a period for each share of common stock it has outstanding.
- To see all exchange delays and terms of use, please see disclaimer.
Chris Linthwaite has an approval rating of 78% among the company’s employees. Chris Linthwaite, president and CEO of Fluidigm, said this about the news boosting FLDM stock up today. Barchart is committed to ensuring digital accessibility for individuals with disabilities. We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests. The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.
In addition to its headquarters and laboratory facility in South San Francisco, California, which it expanded in 2014, the company in 2005 established the first biochip manufacturing facility in Singapore. The Singapore facility was in 2009 led by Grace Yow, who also held the position of Fluidigm vice president of worldwide manufacturing. The Maxpar Human Immuno-Oncology IMC Panel Kit enables interrogation of the tumor microenvironment including activated tumor- infiltrating lymphocytes in FFPE tissue sections using 18-plex IMC.
Bloomberg
Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits , assays, and reagents.
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. Live educational sessions using site features to explore today’s markets. Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.
10x Genomics Stock: Bull vs. Bear – The Motley Fool
10x Genomics Stock: Bull vs. Bear.
Posted: Wed, 24 Nov 2021 08:00:00 GMT [source]
Any other use, including for any commercial purposes, is strictly prohibited without our express prior written consent. Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Provides a general description of the business conducted by this company. A thumbnail of a daily chart is provided, with a link to open and customize a full-sized chart. Bloomberg Markets The Close Romaine Bostick breaks down the day’s top stories and trading action leading into the close.
Price and EPS Surprise Chart
Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. In May 2021, Fluidigm introduced CyTOF XT, a forth-generation CyTOF platform that enables system-level biology at single-cell resolution, designed for clinical trials. CyTOF technology provides a high-resolution proteomic profile of each cell, which distinguishes it from all other cells and reveals the heterogeneity of the sample. The C1 Single-Cell Auto Prep, or C1 system, was released in the early 2000s aimed at delivering 96 single-cell capture and processing events in parallel.
Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The Price and 12 Month EPS chart displays the company’s stock price along with the trailing twelve month EPS. A company’s earnings per share, or EPS, is a key financial metric on its income statement that investors and analysts use to assess its performance and stock price. EPS is the net income, or profit, a company generates during a period for each share of common stock it has outstanding. Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Sufficient IFCs, Control Line Fluid syringes and reagents for 1,920 samples and quality controls. Testing is limited to Laboratories which are certified under the Clinical Laboratory Improvement Amendments of 1988 , 42 U.S.C. §263a, and meet requirements to perform high complexity tests. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is only for use under the Food and Drug Administration’s Emergency Use Authorization. The kit enables unique barcoding of 20 samples so they can be combined and subsequently stained and acquired as one multiplexed sample, followed by software debarcoding and individual sample analysis.
About Fluidigm Corporation
Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value why skillz stock fell sharply today with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.
The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. The company’s Stock price change every day as a result of market forces. If more people want to buy a stock than sell it , then the price moves up. Conversely, if more people wanted to sell a stock than buy it, there would be greater supply than demand, and the price would fall.
More from InvestorPlace
This panel kit includes 17 pathologist- verified antibodies and a nucleic acid stain. The kit combines the Maxpar Human Tumor-Infiltrating Lymphocytes IMC Panel Kit , Maxpar Human Immune Activation IMC Panel Kit , and Maxpar Human Tissue Architecture IMC Panel Kit . Our customers rely on our groundbreaking technology to transform their insights into actionable data. Not every technology used by America’s spy agencies is brewed up in some secret James Bond-style lab.
Standard BioTools Inc. is an American company engaged in the design, manufacture and sale of biological research equipment based on integrated fluidic circuit technology. The company’s founders leveraged their semiconductor experience to create integrated circuits that carried fluids rather than electrons. In 2009, the company was described as “the world’s leading manufacturer of microfluidic devices.” Among the applications to which the company’s products are put to use are protein crystallization, genotyping, DNA analysis and PCR. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit ;… The company was founded in 1999 as “Mycometrix” by Stephen Quake and Gajus Worthington.
Below are the latest news stories about Fluidigm Corp that investors may wish to consider to help them evaluate FLDM as an investment opportunity. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. 30 employees have rated Fluidigm Chief Executive Officer Chris Linthwaite on Glassdoor.com.
Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed https://day-trading.info/ its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Broker recommendations are issued over a particular period of time. Each brokerage firm has its own way of rating that may make it difficult to compare broker recommendations between the brokerage houses.
The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA. StockInvest.us is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon StockInvest.us.
Real-time analyst ratings, insider transactions, earnings data, and more. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.
FLDM Related stocks
Given the rapid developments of research tools and pre-clinical applications in the I/O field, we are excited to see how these disease monitoring technologies will continue to evolve. To see all exchange delays and terms of use, please see disclaimer. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Visit Performance Disclosure for information about the performance numbers displayed above.